Category News

Ionis Pharmaceuticals Partner Biogen Reports Positive Phase 2 Results for Diranersen in Early Alzheimer’s Disease

Ionis and Biogen Report Promising Phase 2 Results for Tau-Targeting Alzheimer’s Therapy Diranersen Ionis Pharmaceuticals and Biogen have announced encouraging topline findings from the Phase 2 CELIA clinical study evaluating diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) therapy designed to…

Read MoreIonis Pharmaceuticals Partner Biogen Reports Positive Phase 2 Results for Diranersen in Early Alzheimer’s Disease

U.S. FDA Approves BeOne Medicines’ BEQALZI™ as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma

BeOne Medicines’ BEQALZI™ Receives U.S. FDA Approval as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma BeOne Medicines has announced that the U.S. Food and Drug Administration has granted accelerated approval to BEQALZI for the treatment of adult…

Read MoreU.S. FDA Approves BeOne Medicines’ BEQALZI™ as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma

Altasciences and Certara Form Strategic Partnership to Advance Early-Stage Drug Development

Altasciences and Certara Form Strategic Partnership to Advance Model-Informed Drug Development Altasciences and Certara have announced a strategic partnership aimed at accelerating early-stage drug development through the integration of model-informed drug development technologies, biosimulation tools, and fully integrated research services.…

Read MoreAltasciences and Certara Form Strategic Partnership to Advance Early-Stage Drug Development
Rocket

Rocket Pharmaceuticals Announces First Quarter 2026 Financial Results and Recent Business Highlights

Rocket Pharmaceuticals Reports First Quarter 2026 Results and Advances Cardiovascular Gene Therapy Pipeline Rocket Pharmaceuticals, a commercial-stage biotechnology company focused on developing genetic therapies for rare and life-threatening disorders, has announced its financial and operational results for the first quarter…

Read MoreRocket Pharmaceuticals Announces First Quarter 2026 Financial Results and Recent Business Highlights

Seek Labs Secures U.S. Patent for Novel Isothermal Molecular Amplification Technology Supporting Decentralized Diagnostic Testing

Seek Labs Secures U.S. Patent for Innovative Isothermal Amplification Technology Designed to Advance Decentralized Molecular Diagnostics Seek Labs, a private TechBio company focused on building programmable platforms to decode, program, and resolve diseases, has announced that the United States Patent…

Read MoreSeek Labs Secures U.S. Patent for Novel Isothermal Molecular Amplification Technology Supporting Decentralized Diagnostic Testing

CareQuest Innovation Partners & PDS Health Partner to Expand Blood Pressure Screening in Dental Clinics

CareQuest Innovation Partners and PDS Health Join Forces to Expand Blood Pressure Screening in Dental Settings, Advancing Integrated Care Delivery CareQuest Innovation Partners and PDS Health have announced a new initiative aimed at expanding blood pressure screening and patient consultation…

Read MoreCareQuest Innovation Partners & PDS Health Partner to Expand Blood Pressure Screening in Dental Clinics

Sensome Study Demonstrates First Accurate Detection of Clot Composition in Fully Blocked Brain Vessels

New Study Demonstrates Sensome’s Clot-Sensing Guidewire Precisely Identifies Clot Composition in Fully Occluded Brain Vessels for the First Time Sensome, a biotechnology innovator specializing in microsensing technology for real-time intra-operative tissue analysis, has announced the publication of groundbreaking first-in-human results…

Read MoreSensome Study Demonstrates First Accurate Detection of Clot Composition in Fully Blocked Brain Vessels

FDA Advisory Panel Backs TRUQAP® (Capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

FDA Advisory Committee Backs TRUQAP® (capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee has delivered a largely favorable assessment of TRUQAP, an investigational targeted therapy developed by AstraZeneca, when used in…

Read MoreFDA Advisory Panel Backs TRUQAP® (Capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer